A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM~1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. In an exemplary embodiment of a noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy of the present disclosure, the method comprises the steps of withdrawing at least one biological sample from a cardiac allograft recipient; and analyzing the at least one biological sample for one or more biomarkers indicative of the presence of fibrin deposits within the cardiac allograft microvasculature; wherein detection of the one or more biomarkers indicates that the cardiac allograft recipient is at-risk for or developing cardiac allograft vasculopathy.

The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.

Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is responsive to a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.

The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.

A method of creating a reperfusion injury can include: providing a cell culture device having an internal chamber with at least one port coupled to a perfusion modulating system capable of modulating perfusion in the internal chamber, wherein the internal chamber includes a cell culture; perfusing a fluid through the internal chamber with the perfusion modulating system, wherein the perfusion modulating system includes at least one pump; reducing fluid flow through the internal chamber; reperfusing fluid flow through the internal chamber; and creating a reperfusion injury in the cell culture by the reperfusion of the fluid flow through the internal chamber. The cell culture includes at least one type of tissue cell. The cell culture can include a tissue construct formed of hydrogel and/or extracellular matrix.

The present disclosure relates to a method for screening a colorectal cancer inhibitor and, more specifically, to a method for screening a colorectal cancer inhibitor wherein a material increasing a binding level of ICAM-1 to SRC is selected as a therapeutic material. In the present disclosure, ICAM-1 is identified to regulate cancer metastasis and angiogenesis in an SRC-dependent manner, thereby exhibiting that ICAM-1 can be a potential target factor for developing a colorectal cancer therapeutic agent. Accordingly, a colorectal cancer therapeutic agent employing the target factor screened by the method of the present disclosure can increase the therapeutic effect for colorectal cancer patients.

Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.

This present disclosure relates to the use of one or more biomarkers for diagnosis, screening, or monitoring aortic aneurysm disease (e.g., ascending aortic aneurysm, descending thoracic aortic aneurysm, abdominal aortic aneurysm and Marfan syndrome) in a biological sample (e.g., a blood sample) of a subject. Accordingly, this disclosure provides methods and kits for determining the presence of one or more biomarkers for aortic aneurysm disease in a biological sample of a subject; methods for using the presence of such biomarkers to predict or diagnose aortic aneurysm disease in a subject; and methods to select or modify a therapeutic regimen (e.g., a beta-blocker treatment) for a subject based on the use of such biomarkers.

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.